Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTSO NYSE:ELMD NYSE:NVRO NASDAQ:PROF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.85+1.0%$0.93$0.71▼$1.61$53.36M1.2868,161 shs15,069 shsELMDElectromed$24.27-1.7%$23.91$17.73▼$35.56$203.29M0.4780,249 shs21,973 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.34$224.32M0.81818,428 shs753,602 shsPROFProfound Medical$5.50+3.6%$4.95$3.76▼$9.17$166.07M0.6678,094 shs102,097 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+0.97%-3.99%-10.79%-9.90%-19.03%ELMDElectromed-1.70%-0.08%+1.80%+28.96%+5.94%NVRONevro0.00%0.00%0.00%0.00%+19.43%PROFProfound Medical+3.58%-0.54%+2.42%-3.17%-23.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTSOCytosorbents$0.85+1.0%$0.93$0.71▼$1.61$53.36M1.2868,161 shs15,069 shsELMDElectromed$24.27-1.7%$23.91$17.73▼$35.56$203.29M0.4780,249 shs21,973 shsNVRONevro$5.85+0.1%$5.85$3.17▼$10.34$224.32M0.81818,428 shs753,602 shsPROFProfound Medical$5.50+3.6%$4.95$3.76▼$9.17$166.07M0.6678,094 shs102,097 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTSOCytosorbents+0.97%-3.99%-10.79%-9.90%-19.03%ELMDElectromed-1.70%-0.08%+1.80%+28.96%+5.94%NVRONevro0.00%0.00%0.00%0.00%+19.43%PROFProfound Medical+3.58%-0.54%+2.42%-3.17%-23.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTSOCytosorbents 2.00Hold$5.50546.91% UpsideELMDElectromed 3.50Strong Buy$36.2549.36% UpsideNVRONevro 2.00Hold$5.36-8.29% DownsidePROFProfound Medical 2.00Hold$11.00100.00% UpsideCurrent Analyst Ratings BreakdownLatest CTSO, NVRO, ELMD, and PROF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025PROFProfound MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/14/2025CTSOCytosorbentsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PROFProfound MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CTSOCytosorbentsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PROFProfound MedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/25/2025ELMDElectromedZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/16/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/27/2025ELMDElectromedLoop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.008/27/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $35.008/27/2025ELMDElectromedLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/20/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTSOCytosorbents$35.60M1.50N/AN/A$0.20 per share4.25ELMDElectromed$64M3.18$0.59 per share41.36$5.10 per share4.76NVRONevro$408.52M0.55N/AN/A$8.10 per share0.72PROFProfound Medical$10.68M15.55N/AN/A$2.01 per share2.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTSOCytosorbents-$20.72M-$0.17N/AN/AN/A-25.58%-111.97%-29.00%11/6/2025 (Estimated)ELMDElectromed$5.15M$0.8432.36∞N/A11.34%15.71%13.37%N/ANVRONevro-$92.21M-$3.05N/AN/AN/A-16.54%-23.52%-10.83%N/APROFProfound Medical-$27.82M-$1.46N/AN/AN/A-343.97%-89.74%-73.06%11/13/2025 (Estimated)Latest CTSO, NVRO, ELMD, and PROF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025Q3 2025PROFProfound Medical-$0.3820N/AN/AN/A$6.99 millionN/A11/6/2025Q3 2025CTSOCytosorbents-$0.06N/AN/AN/A$10.02 millionN/A8/14/2025Q2 2025PROFProfound Medical-$0.43-$0.52-$0.09-$0.52$4.75 million$2.21 million8/7/2025Q2 2025CTSOCytosorbents-$0.07-$0.05+$0.02$0.03$9.79 million$9.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTSOCytosorbentsN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ANVRONevroN/AN/AN/AN/AN/APROFProfound MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTSOCytosorbents1.242.341.96ELMDElectromedN/A5.104.74NVRONevro0.675.023.76PROFProfound Medical0.118.537.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTSOCytosorbents32.87%ELMDElectromed40.82%NVRONevro95.52%PROFProfound Medical47.86%Insider OwnershipCompanyInsider OwnershipCTSOCytosorbents7.30%ELMDElectromed10.50%NVRONevro3.20%PROFProfound Medical1.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTSOCytosorbents22062.76 million58.18 millionOptionableELMDElectromed1608.38 million7.36 millionOptionableNVRONevro1,09038.37 million36.27 millionOptionablePROFProfound Medical15030.19 million29.74 millionOptionableCTSO, NVRO, ELMD, and PROF HeadlinesRecent News About These CompaniesA ‘profound initiative’: UNC will open Colorado’s third medical schoolOctober 20, 2025 | gazette.comGProfound Medical announces Busch Center completed 500th TULSA procedureOctober 16, 2025 | msn.comProfound Medical Congratulates the Busch Center for Achieving 500th TULSA Procedure MilestoneOctober 16, 2025 | financialpost.comFProfound Medical to Present at Stifel 2025 Healthcare ConferenceOctober 14, 2025 | msn.comProfound Medical to Participate in the Stifel 2025 Healthcare ConferenceOctober 14, 2025 | financialpost.comFProfound Medical to Participate in the Stifel 2025 Healthcare ConferenceOctober 14, 2025 | globenewswire.comProfound Medical's (PROF) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 10, 2025 | marketbeat.comGagnon Securities LLC Boosts Stake in Profound Medical $PROFOctober 8, 2025 | marketbeat.comProfound Medical sees Q3 revenue $5.2M-$5.3M vs. $2.8M last yearOctober 7, 2025 | msn.comProfound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third QuarterOctober 7, 2025 | globenewswire.comProfound Medical (NASDAQ:PROF) Stock Price Up 2% - Here's What HappenedSeptember 27, 2025 | marketbeat.comProfound Medical: Expectations WorsenSeptember 25, 2025 | seekingalpha.comProfound Medical announces launch of TULSA by Texas Prostate, Dallas MedicalSeptember 23, 2025 | msn.comTexas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate TreatmentSeptember 23, 2025 | financialpost.comFTexas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate TreatmentSeptember 23, 2025 | globenewswire.comHow Its Possible to Turn a $7,000 TFSA Into $50,000September 19, 2025 | msn.comProfound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth ConferenceAugust 28, 2025 | globenewswire.comProfound Medical is a buy, Leede saysAugust 20, 2025 | cantechletter.comCProfound Medical: Smokes Is Everywhere, Initiate At SellAugust 18, 2025 | seekingalpha.comProfound Medical Second Quarter 2025 Earnings: Misses ExpectationsAugust 16, 2025 | finance.yahoo.comProfound Medical Corp. (NASDAQ:PROF) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTSO, NVRO, ELMD, and PROF Company DescriptionsCytosorbents NASDAQ:CTSO$0.85 +0.01 (+0.97%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$0.86 +0.01 (+0.68%) As of 10/24/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.Electromed NYSE:ELMD$24.27 -0.42 (-1.70%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$24.24 -0.02 (-0.10%) As of 10/24/2025 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Nevro NYSE:NVRONevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Profound Medical NASDAQ:PROF$5.50 +0.19 (+3.58%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.48 -0.01 (-0.27%) As of 10/24/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
